Atlas Trials

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Clinical trial NCT03937219 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03937219
Sponsor
Exelixis
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Renal Cell Carcinoma
Start date
2019-06-25
Primary completion
2022-01-31
Enrollment
855

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.